Home / Deep Research / Human Papillomavirus Infection

Human Papillomavirus Infection

1. Disease Information

2026-07-01
Falcon MONDO:0005161 Model: Edison Scientific Literature 62 citations

1. Disease Information

Overview

Human papillomavirus (HPV) is a non-enveloped, double-stranded circular DNA virus belonging to the family Papillomaviridae, with a genome of approximately 8 kilobases (jain2023epidemiologymolecularpathogenesis pages 3-5). It is the most common sexually transmitted viral infection globally, with over 400 identified types and more than 200 characterized variants (wu2024unveilingthemultifaceted pages 1-2, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2). HPV causes approximately 5% of all human cancers worldwide and is implicated in virtually all cervical cancers (99.7%), as well as substantial proportions of anal (71–90%), vaginal (65–74%), vulvar (43–74%), penile (43–63%), and oropharyngeal (10–70%) cancers (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2). Over 80% of sexually active individuals will contract HPV by age 45, though approximately 90% of infections resolve spontaneously within two years (baba2025humanpapillomavirus pages 1-2).

Key Identifiers and Synonyms

The following table summarizes key disease identifiers, classification schemes, and terminology for HPV infection:

Table (click to expand)
Identifier Type Value/Code Description
MONDO ID MONDO:0005161 Human papilloma virus infection; disease ontology identifier used in aggregated disease knowledge resources and Open Targets disease-target associations (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)
ICD-10 B97.7 Papillomavirus as the cause of diseases classified elsewhere; used when HPV is the etiologic infectious agent rather than the primary lesion diagnosis (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)
ICD-10 A63.0 Anogenital (venereal) warts / condylomata acuminata; typically caused by low-risk HPV, especially types 6 and 11 (maghiar2024skinlesionscaused pages 4-6, branda2024humanpapillomavirus(hpv) pages 7-9)
ICD-10 B07 Viral warts; includes common cutaneous wart presentations caused by cutaneous HPV types (maghiar2024skinlesionscaused pages 4-6, maghiar2024skinlesionscaused pages 2-4)
ICD-11 1F9 Viral infections characterized by skin and mucous membrane lesions; parent infectious-disease grouping under which HPV-related wart disorders are classified in ICD-11 usage contexts (maghiar2024skinlesionscaused pages 4-6)
ICD-11 1F9Y / specific child codes Other specified viral infections of skin or mucosa may be used depending on lesion site; HPV-associated neoplasia is coded separately by cancer site (e.g., cervix, anus, oropharynx) rather than by HPV alone (branda2024humanpapillomavirus(hpv) pages 7-9, baba2025humanpapillomavirus pages 10-11)
MeSH D030361 Papillomavirus Infections; MeSH disease heading for indexing biomedical literature on HPV infection and related manifestations (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma)
Common synonyms HPV infection Standard clinical shorthand for infection with human papillomavirus; most common contemporary synonym (jain2023epidemiologymolecularpathogenesis pages 2-3, malik2023trackinghpvinfection pages 1-2)
Common synonyms Human papillomavirus infection Expanded formal disease name used in reviews and public-health literature (wu2024unveilingthemultifaceted pages 1-2, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2)
Common synonyms Papillomavirus infection Broader synonym used in classification/pathogenesis literature; may require context to distinguish human from animal papillomavirus infection (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2, bette2024cottontailrabbitpapillomavirus pages 1-2)
Common synonyms Condylomata acuminata Synonym for anogenital warts, a common low-risk HPV manifestation (maghiar2024skinlesionscaused pages 4-6, branda2024humanpapillomavirus(hpv) pages 7-9)
HPV risk classification High-risk (oncogenic) types High-risk mucosal types include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68; these are linked to cervical, anal, penile, vulvar, vaginal, and oropharyngeal cancers. HPV16 and HPV18 account for most cervical cancers (jain2023epidemiologymolecularpathogenesis pages 2-3, pavelescu2025molecularinsightsinto pages 2-4, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2, jain2023epidemiologymolecularpathogenesis pages 3-5)
HPV risk classification Low-risk types Low-risk types include HPV6 and HPV11, with additional low-risk mucosal types such as 40, 42, 43, 44, 54, 61, 72, 81, 89; these mainly cause benign lesions such as genital warts and respiratory papillomas (wu2024unveilingthemultifaceted pages 1-2, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2, maghiar2024skinlesionscaused pages 4-6)
Taxonomic classification Alpha papillomavirus Predominantly infects genital and oral mucosa; includes both low-risk and high-risk mucosal HPV types associated with anogenital lesions and many HPV-related cancers (wu2024unveilingthemultifaceted pages 1-2, jain2023epidemiologymolecularpathogenesis pages 3-5)
Taxonomic classification Beta papillomavirus Primarily cutaneous; commonly found on skin and implicated in some non-melanoma skin cancers, especially in immunocompromised hosts (wu2024unveilingthemultifaceted pages 1-2, bette2024cottontailrabbitpapillomavirus pages 2-3)
Taxonomic classification Gamma papillomavirus Primarily associated with cutaneous infection and skin tropism (wu2024unveilingthemultifaceted pages 1-2)
Taxonomic classification Mu papillomavirus Cutaneous genus associated with skin wart phenotypes (wu2024unveilingthemultifaceted pages 1-2)
Taxonomic classification Nu papillomavirus Cutaneous genus associated with skin wart phenotypes (wu2024unveilingthemultifaceted pages 1-2)

Table: This table summarizes key disease identifiers and classification schemes for human papillomavirus infection, including ontology and coding systems, common synonyms, oncogenic risk groupings, and viral genera. It is useful as a compact reference for mapping HPV across clinical coding, biomedical indexing, and biological classification systems.

Common Synonyms: HPV infection, human papillomavirus infection, papillomavirus infection, condylomata acuminata (for anogenital warts), genital warts, venereal warts, verruca vulgaris (common warts).

2. Etiology

Disease Causal Factors

HPV infection is caused by infection with human papillomavirus, a DNA virus transmitted primarily through direct contact with infected skin or mucous membranes, most commonly via sexual contact (maghiar2024skinlesionscaused pages 2-4). The virus targets basal epithelial cells and enters through microabrasions or disruptions in the epithelial barrier (jain2023epidemiologymolecularpathogenesis pages 3-5). Non-sexual transmission routes include perinatal transmission and autoinoculation (jain2023epidemiologymolecularpathogenesis pages 3-5).

Risk Factors

Environmental and Behavioral Risk Factors: - Multiple sexual partners and early onset of sexual activity (peak infection in teens and twenties) (jain2023epidemiologymolecularpathogenesis pages 2-3, pavelescu2025molecularinsightsinto pages 2-4) - High parity and early pregnancy (pavelescu2025molecularinsightsinto pages 2-4) - Long-term oral contraceptive use (pavelescu2025molecularinsightsinto pages 2-4) - Tobacco smoking and tobacco chewing (pavelescu2025molecularinsightsinto pages 2-4) - Concurrent sexually transmitted infections, particularly HIV (jain2023epidemiologymolecularpathogenesis pages 2-3) - Immunosuppression (baba2025humanpapillomavirus pages 1-2) - Male homosexuality (HPV anal infection prevalence ≥90% in homosexual and HIV-infected men) (jain2023epidemiologymolecularpathogenesis pages 2-3)

Host Genetic Risk Factors: Heritability estimates for cervical carcinoma liability range from 27–29% (olokede2026areviewon pages 6-7). Genome-wide association studies (GWAS) have identified HLA class II loci, particularly HLA-DRB1 and HLA-DQB1, as the strongest genetic determinants of HPV persistence and cervical cancer susceptibility (olokede2026areviewon pages 6-7, olokede2026areviewon pages 1-2). Specific risk alleles include HLA-DRB115:01, HLA-DQB106:02, HLA-DRB113:02, HLA-DQB105:02, and HLA-DRB1*03:01 (olokede2026areviewon pages 6-7, pavelescu2025molecularinsightsinto pages 11-13). Additional GWAS loci outside the MHC region include GSDMB (pyroptosis regulation), MUC1 (mucosal barrier), DSG2/CDH1 (epithelial adhesion), and TFAP2A (differentiation pathway) (olokede2026areviewon pages 16-17).

Protective Factors

Genetic Protective Factors: HLA-DRB113:01 and HLA-DQB106:03 confer protection through superior binding dynamics for conserved E6/E7 epitopes, facilitating robust Th1 immune responses (olokede2026areviewon pages 6-7). HLA-DRB115:03 was associated with decreased risk of persistent high-risk HPV (olokede2026areviewon pages 6-7). Notably, DRB11302-positive women had significantly lower cumulative progression rates to CIN3 (2.1% vs 14.0%) over 10 years (li2025biomarkersdifferentiatingregression pages 8-9).

Environmental Protective Factors: - HPV vaccination (most effective preventive measure) (wu2024unveilingthemultifaceted pages 9-10) - Consistent condom use and limiting sexual partners (wu2024unveilingthemultifaceted pages 9-10) - Male circumcision (uncircumcised men have greater genital mucosa exposure) (baba2025humanpapillomavirus pages 10-11)

Gene-Environment Interactions

DNA repair capacity variants interact with tobacco smoke mutagens to influence HPV-driven carcinogenesis, and estrogen receptor polymorphisms (ESR1 PvuII and XbaI variants) interact with exogenous steroid hormones to upregulate viral E6/E7 oncogenes (olokede2026areviewon pages 19-21). Progesterone signaling upregulates DNA methyltransferases (DNMT1, DNMT3B) to promote hypermethylation of tumor suppressor genes (olokede2026areviewon pages 19-21). Vaginal dysbiosis and mucosal barrier dynamics represent additional relevant gene-environment interaction factors (olokede2026areviewon pages 19-21).

3. Phenotypes

Clinical Manifestations

Cutaneous Warts: - Common warts (verruca vulgaris), plantar warts, flat warts - Cutaneous warts affect 7–12% of the population, with higher prevalence in children and adolescents (10–20% annual incidence) (maghiar2024skinlesionscaused pages 2-4) - HPO terms: HP:0200043 (Verrucae), HP:0010283 (Verruca plana)

Anogenital Warts (Condylomata Acuminata): - Caused primarily by HPV types 6 and 11 (branda2024humanpapillomavirus(hpv) pages 7-9) - Develop several months after infection; often asymptomatic but may cause itching and bleeding (branda2024humanpapillomavirus(hpv) pages 7-9) - HPO terms: HP:0030799 (Condylomata acuminata)

Cervical Intraepithelial Neoplasia (CIN): - CIN1: reflects transient infection, low-grade squamous intraepithelial lesion (LSIL) (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2) - CIN2: variable malignant potential, intermediate-grade lesion (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, li2025biomarkersdifferentiatingregression pages 6-7) - CIN3: most significant precursor to invasive cervical cancer (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2) - HPO terms: HP:0032260 (Cervical intraepithelial neoplasia)

HPV-Associated Cancers: - Cervical cancer (virtually all cases HPV-attributable; HPV16 accounts for 55%, HPV18 for 15%) (jain2023epidemiologymolecularpathogenesis pages 3-5) - Oropharyngeal squamous cell carcinoma (rising rapidly in developed countries) (baba2025humanpapillomavirus pages 1-2) - Anal cancer (90% HPV-attributable) (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2) - Penile, vulvar, and vaginal cancers (baba2025humanpapillomavirus pages 1-2) - HPO terms: HP:0012126 (Cervical squamous cell carcinoma), HP:0100649 (Neoplasm of the oral cavity)

Quality of Life Impact: HPV-associated cancers impose significant morbidity and mortality. In 2020, cervical cancer alone accounted for 604,127 new cases and 341,831 deaths globally, making it the second most common cancer in women aged 15–44 (jain2023epidemiologymolecularpathogenesis pages 2-3).

4. Genetic/Molecular Information

Viral Genome Structure

The HPV genome (~8 kb) consists of early genes (E1, E2, E4, E5, E6, E7) and late genes (L1, L2) (jain2023epidemiologymolecularpathogenesis pages 3-5, bette2024cottontailrabbitpapillomavirus pages 2-3). The early gene products control viral replication, transcription regulation, and cellular transformation, while L1 and L2 encode the viral capsid proteins.

Oncoproteins and Molecular Mechanisms

The following table summarizes the key molecular mechanisms of HPV oncoproteins:

Table (click to expand)
Viral Protein Host Target Mechanism Signaling Pathway Biological Consequence
E6 TP53 (p53) via E6AP/UBE3A Forms E6–E6AP complex that ubiquitinates and degrades p53 p53/cell-cycle checkpoint, apoptosis Loss of G1/S arrest, impaired DNA-damage response, reduced apoptosis, mutation accumulation (martinelli2025molecularmechanismsand pages 4-5, wu2024unveilingthemultifaceted pages 2-3, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6)
E6 hTERT promoter/telomerase machinery Induces hTERT expression and telomerase activation Telomere maintenance/immortalization Cellular immortalization and prolonged survival of infected cells (wu2024unveilingthemultifaceted pages 2-3, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, kao2026theroleof pages 3-5)
E6 PTEN/TSC2 and upstream PI3K regulators Inactivates PTEN and promotes mTOR signaling, enhancing PI3K/AKT activity PI3K/AKT/mTOR Increased proliferation, survival, autophagy inhibition, treatment resistance (baba2025humanpapillomavirus pages 6-8, martinelli2025molecularmechanismsand pages 4-5, pavelescu2025molecularinsightsinto pages 8-10)
E6 β-catenin regulatory axis Stabilizes/activates nuclear β-catenin and oncogenic transcription Wnt/β-catenin Upregulation of c-Myc/cyclin D1, enhanced growth and transformation (baba2025humanpapillomavirus pages 6-8, pavelescu2025molecularinsightsinto pages 8-10)
E6 NOTCH1 and associated control of differentiation Disrupts NOTCH1 signaling and p53-linked differentiation/senescence programs Notch signaling Loss of differentiation, escape from senescence, tumor progression (baba2025humanpapillomavirus pages 6-8, martinelli2025molecularmechanismsand pages 4-5, pavelescu2025molecularinsightsinto pages 8-10)
E7 RB1 (pRb) via LXCXE motif Binds pocket proteins and promotes pRb degradation/inactivation pRb/E2F cell-cycle control Unchecked G1-to-S progression and viral/cellular DNA synthesis (martinelli2025molecularmechanismsand pages 4-5, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6)
E7 E2F transcription factors Releases E2F after pRb inactivation E2F-driven transcription Increased S-phase entry, replication gene expression, uncontrolled proliferation (martinelli2025molecularmechanismsand pages 4-5, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6)
E7 Centrosome duplication machinery Perturbs centrosome control and mitotic fidelity Chromosomal stability/mitotic control Aneuploidy, chromosomal instability, invasive transformation (martinelli2025molecularmechanismsand pages 5-7)
E5 EGFR Enhances EGFR signaling and downstream kinase activation EGFR/MAPK/ERK, PI3K/AKT Increased proliferation, survival, migration, oncogene induction (including c-Fos) (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3, pavelescu2025molecularinsightsinto pages 8-10)
E5 MHC-I trafficking machinery Retains MHC-I in ER/Golgi and reduces surface antigen presentation Antigen presentation/immune evasion Reduced CD8+ T-cell recognition and viral persistence (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3)
E5 STING (TMEM173) innate sensing pathway Interferes with STING signaling and downstream interferon induction cGAS–STING / innate antiviral response Blunted interferon response and enhanced immune escape/persistence (vallejoruiz2024molecularaspectsof pages 2-3)
APOBEC3B induction in HPV-driven cells Host genomic DNA (cytidines), linked to E6-driven dysregulation Cytidine deamination produces APOBEC mutational signatures and hotspot mutations APOBEC mutagenesis / genomic instability C→T transition burden, oncogenic mutations (e.g., PIK3CA hotspots), malignant progression (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4, janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6)

Table: This table summarizes the major HPV molecular mechanisms most relevant to persistence, immune evasion, and carcinogenesis. It highlights how E5, E6, E7, and APOBEC-associated processes map onto host targets and signaling pathways.

E6 Oncoprotein: E6 forms a complex with E6-associated protein (E6AP/UBE3A), an E3 ubiquitin ligase, to target p53 for proteasomal degradation, eliminating G1/S checkpoint control and DNA damage response (wu2024unveilingthemultifaceted pages 2-3, mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11, baba2025humanpapillomavirus pages 4-6). E6 additionally induces hTERT expression for cellular immortalization, activates PI3K/AKT/mTOR signaling (inhibiting autophagy and promoting proliferation), stabilizes Wnt/β-catenin signaling (upregulating c-Myc and cyclin D1), and disrupts Notch1 signaling (baba2025humanpapillomavirus pages 6-8, pavelescu2025molecularinsightsinto pages 8-10). E6 also inhibits extrinsic apoptosis by interacting with FADD and caspase-8 and suppresses IRF-3 to diminish immune responses (wu2024unveilingthemultifaceted pages 2-3).

E7 Oncoprotein: E7 binds retinoblastoma protein (pRb) and related pocket proteins (p107, p130) through the LXCXE binding motif, causing their ubiquitination and proteasomal degradation (baba2025humanpapillomavirus pages 4-6). This releases E2F transcription factors, driving S-phase cell cycle progression (martinelli2025molecularmechanismsand pages 4-5, baba2025humanpapillomavirus pages 4-6). E7 also disrupts centrosome duplication leading to chromosomal instability, activates DNA methyltransferases causing aberrant epigenetic modifications, and modulates STAT1, NF-κB, IRF1, and SMAD2/3 transcription factors (martinelli2025molecularmechanismsand pages 4-5, martinelli2025molecularmechanismsand pages 5-7).

E5 Oncoprotein: E5 enhances EGFR signaling to activate MAPK/ERK and PI3K/AKT pathways, promoting proliferation and survival (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3). E5 mediates immune evasion by retaining MHC-I molecules in the ER/Golgi, reducing antigen presentation, and by interfering with STING signaling to suppress interferon responses (vallejoruiz2024molecularaspectsof pages 2-3).

Viral Integration and Genomic Instability

HPV integration into the host genome occurs in 70–85% of HPV-positive cancers and represents a critical transition from infection to malignancy (martinelli2025molecularmechanismsand pages 5-7). Integration typically disrupts the E2 gene, removing its suppressive effect on E6/E7 expression and allowing unrestricted oncoprotein activity (kao2026theroleof pages 3-5, janiszewska2025hpvdrivenoncogenesis—muchmore pages 1-3). Integration occurs at fragile sites in the host genome and causes direct genomic instability through disruption of tumor suppressor genes and upregulation of oncogenes (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4, martinelli2025molecularmechanismsand pages 5-7).

APOBEC Mutagenesis

A recently characterized non-canonical mechanism involves APOBEC3B enzymes, which are activated by interferon-mediated immune responses to viral nucleic acids. These enzymes mediate cytidine deamination, generating C→T transition mutations in the host genome that promote malignant transformation (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4). E6 oncoprotein expression drives APOBEC3B overexpression through TP53 degradation and TEAD transcription factor activation. APOBEC has been identified as the dominant mutational signature in HPV16+ oropharyngeal cancers, with direct links to oncogenic mutations such as PIK3CA E542K/E545K hotspots (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4, janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6).

HPV-Derived miRNAs

Five putative HPV16-encoded miRNAs (miR-H1, H2, H3, H5, H6) have been identified, showing low-level expression in cervical lesions (janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6). These may contribute to immune escape, cell cycle deregulation, and tumor suppressor attenuation, though significant inconsistencies exist between research groups regarding their targets and functional significance (janiszewska2025hpvdrivenoncogenesis—muchmore pages 6-7, janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6).

Epigenetic Changes

DNA methylation represents one of the earliest and most clinically informative epigenetic alterations in HPV-driven carcinogenesis (legaki2026hpvdrivencervicalcarcinogenesis pages 4-5). E7 activates DNA methyltransferases causing aberrant hypermethylation of tumor suppressor genes including CDKN2A and CDH1 (olokede2026areviewon pages 16-17, baba2025humanpapillomavirus pages 4-6). Host gene methylation biomarkers including FAM19A4, CADM1, PAX1, and MAL show promise for detecting high-grade intraepithelial lesions (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, li2025biomarkersdifferentiatingregression pages 8-9). DNMT3B polymorphisms (-149C>T) promote hypermethylation of tumor suppressors (olokede2026areviewon pages 16-17).

5. Environmental Information and Infectious Agent

Infectious Agent

Pathogen: Human papillomavirus (HPV), Family Papillomaviridae, small non-enveloped DNA virus (NCBI Taxonomy ID: 10566 for HPV16)

HPV is classified into five genera (alpha, beta, gamma, mu, nu), with the alpha genus being most clinically significant for mucosal infections and malignancies (wu2024unveilingthemultifaceted pages 1-2). At least 14 high-risk types (Group 1 carcinogens per IARC) are recognized: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (pavelescu2025molecularinsightsinto pages 2-4). HPV is resistant to many disinfectants and relatively unsusceptible to external conditions (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2).

Lifestyle and Environmental Cofactors

Tobacco smoking, UV radiation exposure (particularly for beta-HPV-associated cutaneous malignancies), long-term hormonal contraceptive use, and high parity act as cofactors that augment HPV-driven carcinogenesis (pavelescu2025molecularinsightsinto pages 2-4).

6. Mechanism / Pathophysiology

Causal Chain: From Infection to Cancer

  1. Initial Infection: HPV gains access to basal epithelial cells through microabrasions in stratified squamous epithelium (jain2023epidemiologymolecularpathogenesis pages 3-5)
  2. Viral Establishment: The virus establishes episomal infection in basal cells, maintaining low copy numbers and utilizing host DNA replication machinery (jain2023epidemiologymolecularpathogenesis pages 3-5)
  3. Immune Evasion: E5 downregulates MHC-I/II and inhibits STING-interferon signaling; E6 suppresses IRF-3; E7 suppresses RIG-I and cGAS-STING pathways (baba2025humanpapillomavirus pages 6-8, vallejoruiz2024molecularaspectsof pages 2-3)
  4. Viral Persistence: In 10–20% of infected women, immune evasion enables chronic infection lasting years (jain2023epidemiologymolecularpathogenesis pages 2-3)
  5. Genomic Integration: Viral DNA integrates into host genome at fragile sites (70–85% of HPV+ cancers), disrupting E2 and unleashing constitutive E6/E7 expression (martinelli2025molecularmechanismsand pages 5-7)
  6. Cellular Transformation: E6-mediated p53 degradation and E7-mediated pRb inactivation abolish cell cycle checkpoints, while APOBEC mutagenesis generates somatic mutations (wu2024unveilingthemultifaceted pages 2-3, baba2025humanpapillomavirus pages 4-6, janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4)
  7. Malignant Progression: Accumulated genetic and epigenetic alterations, chromosomal instability, and immune microenvironment remodeling drive progression from CIN to invasive carcinoma (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, martinelli2025molecularmechanismsand pages 5-7)

Key Signaling Pathways

Cell Types Involved

  • Basal keratinocytes (CL:0000312): Primary target cells for HPV infection
  • Cervical epithelial cells (CL:0002535): Site of cervical carcinogenesis
  • CD4+ T helper cells (CL:0000492): Critical for HPV clearance; modulated by HLA-mediated antigen presentation
  • CD8+ cytotoxic T cells (CL:0000794): Effector cells for eliminating HPV-infected cells

7. Anatomical Structures Affected

Organ Level

  • Primary organs: Uterine cervix (UBERON:0000002), oropharynx (UBERON:0001729), anus (UBERON:0001245), vulva, vagina, penis
  • Secondary involvement: Regional lymph nodes (metastatic spread), respiratory tract (laryngeal papillomatosis)
  • Body systems: Reproductive system, integumentary system, upper aerodigestive tract

Tissue and Cell Level

  • Tissues affected: Stratified squamous epithelium (mucosal and cutaneous), transformation zone of cervix
  • Specific cell populations: Basal epithelial cells (primary viral targets), squamous epithelial cells at various differentiation stages

Localization

HPV infection sites correspond to virus-epithelium tropism. Alpha-HPV types predominantly affect anogenital and oropharyngeal mucosal epithelium, while beta, gamma, mu, and nu types primarily affect cutaneous epithelium (wu2024unveilingthemultifaceted pages 1-2). HPV-associated lesions can be bilateral and multifocal.

8. Temporal Development

Onset

  • Age of acquisition: Peak incidence in sexually active teens and young adults (jain2023epidemiologymolecularpathogenesis pages 2-3)
  • Onset pattern: Typically insidious; infection is usually asymptomatic, with clinical manifestations developing weeks to years after exposure (branda2024humanpapillomavirus(hpv) pages 7-9)

Progression

  • Natural history: Most infections (approximately 90%) resolve spontaneously within 1–2 years through immune clearance (baba2025humanpapillomavirus pages 1-2). Persistent infection with high-risk types over years to decades may progress through CIN1 → CIN2 → CIN3 → invasive carcinoma (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2)
  • Disease duration: Self-limited in most cases; chronic lifelong in persistent infections
  • Critical period: The interval between persistent high-risk HPV infection and invasive cancer development typically spans 10–20 years, providing a window for screening and intervention

9. Inheritance and Population

Epidemiology

Host Genetic Architecture

While HPV infection itself is infectious (not inherited), host genetic susceptibility to persistent infection and cancer development follows a polygenic architecture, with heritability estimates of 27–29% for cervical carcinoma liability (olokede2026areviewon pages 6-7). HLA allele frequencies vary dramatically across geographic ancestries, with protective alleles more prevalent in European populations but absent in sub-Saharan African cohorts where cervical cancer burden is highest (olokede2026areviewon pages 6-7).

Population Demographics

10. Diagnostics

Clinical Tests

Biomarkers

Self-Sampling

Modern guidelines, including 2025 ASCCP recommendations, advocate for self-collected vaginal samples for high-risk HPV testing to improve screening accessibility, with WHO targeting 70% of women screened by 2030 (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2, maghiar2024skinlesionscaused pages 6-7).

11. Outcome/Prognosis

Survival and Mortality

Prognostic Biomarkers

12. Treatment

The following table provides a comprehensive overview of current and emerging HPV treatment and prevention approaches:

Table (click to expand)
Category Intervention Mechanism/Description Evidence Level
Physical treatment Cryotherapy Liquid nitrogen freezing destroys visible HPV-associated lesions such as warts; commonly used office-based ablative treatment (jain2023epidemiologymolecularpathogenesis pages 12-13, maghiar2024skinlesionscaused pages 6-7) Established clinical practice / guideline-supported review evidence
Physical treatment LEEP Loop electrosurgical excision procedure removes cervical transformation-zone tissue and is used for treatment of high-grade cervical intraepithelial lesions (jain2023epidemiologymolecularpathogenesis pages 12-13) Established clinical practice / guideline-supported review evidence
Physical treatment Electrocautery Thermal destruction/removal of wart tissue or dysplastic lesions; used for anogenital and cutaneous lesions (jain2023epidemiologymolecularpathogenesis pages 12-13, maghiar2024skinlesionscaused pages 6-7) Established clinical practice / review evidence
Physical treatment Laser therapy CO2 or related laser ablation for extensive, refractory, or anatomically difficult lesions (jain2023epidemiologymolecularpathogenesis pages 12-13, maghiar2024skinlesionscaused pages 6-7) Established clinical practice / review evidence
Physical treatment Surgical excision Direct removal of resistant or suspicious lesions; effective but may require anesthesia and can scar (maghiar2024skinlesionscaused pages 7-9, maghiar2024skinlesionscaused pages 6-7) Established clinical practice / review evidence
Chemical treatment Salicylic acid Topical keratolytic that gradually destroys hyperkeratotic wart tissue; requires repeated application (maghiar2024skinlesionscaused pages 7-9, maghiar2024skinlesionscaused pages 6-7) Established clinical practice / review evidence
Chemical treatment Cantharidin Vesicant topical agent that induces blistering and separation of lesion tissue in wart management (maghiar2024skinlesionscaused pages 7-9, maghiar2024skinlesionscaused pages 6-7) Established clinical practice / review evidence
Immunomodulatory Imiquimod (TLR7 agonist) Activates TLR7-mediated innate immune signaling to enhance local antiviral immune response; used particularly for anogenital warts (jain2023epidemiologymolecularpathogenesis pages 12-13, OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma) Approved targeted therapy / OpenTargets-supported association
Prophylactic vaccine Cervarix (bivalent) L1 virus-like particle vaccine targeting HPV16/18 to prevent acquisition of high-risk infection and cervical precancer/cancer (jain2023epidemiologymolecularpathogenesis pages 12-13, wu2024unveilingthemultifaceted pages 9-10, jain2023epidemiologymolecularpathogenesis pages 10-12) High-level evidence; licensed vaccine
Prophylactic vaccine Gardasil (quadrivalent) L1 VLP vaccine targeting HPV6/11/16/18; prevents genital warts and high-risk HPV infection (wu2024unveilingthemultifaceted pages 9-10, jain2023epidemiologymolecularpathogenesis pages 10-12) High-level evidence; licensed vaccine
Prophylactic vaccine Gardasil 9 (nonavalent) Expanded L1 VLP vaccine covering HPV6/11/16/18/31/33/45/52/58; broadest currently licensed prophylactic coverage in many settings (jain2023epidemiologymolecularpathogenesis pages 12-13, wu2024unveilingthemultifaceted pages 9-10, jain2023epidemiologymolecularpathogenesis pages 10-12) High-level evidence; licensed vaccine
Prophylactic vaccine Cecolin Bivalent prophylactic HPV vaccine included among currently available VLP-based vaccines (jain2023epidemiologymolecularpathogenesis pages 10-12) Licensed/implementation evidence in reviews
Prophylactic vaccine Cervavax Quadrivalent prophylactic HPV vaccine included in current vaccine landscape reviews (jain2023epidemiologymolecularpathogenesis pages 12-13, jain2023epidemiologymolecularpathogenesis pages 10-12) Licensed/implementation evidence in reviews
Therapeutic vaccine Viral vector-based vaccines Experimental vaccines deliver HPV antigens, usually E6/E7, via viral vectors to induce cell-mediated clearance of infected/transformed cells (branda2024humanpapillomavirus(hpv) pages 5-6, jain2023epidemiologymolecularpathogenesis pages 22-24) Early-phase/experimental
Therapeutic vaccine DNA-based vaccines Plasmid/DNA immunization strategies encoding HPV antigens aim to generate cytotoxic T-cell responses against established infection or dysplasia (jain2023epidemiologymolecularpathogenesis pages 22-24) Early-phase/experimental
Chemotherapy Cisplatin-based combinations Standard systemic therapy for advanced cervical cancer; combinations with bevacizumab, topotecan, paclitaxel, 5-FU, or bleomycin improve antitumor activity in selected settings (baba2025humanpapillomavirus pages 15-17) Standard oncology practice / review evidence
Immunotherapy Pembrolizumab Immune checkpoint inhibitor targeting PD-1; used in HPV-related cancers, especially recurrent/metastatic cervical cancer and other advanced HPV-driven malignancies (maghiar2024skinlesionscaused pages 7-9, baba2025humanpapillomavirus pages 15-17) Approved/late-stage oncology evidence
Immunotherapy Nivolumab PD-1 checkpoint blockade investigated/used in HPV-associated cancers to restore antitumor T-cell function (baba2025humanpapillomavirus pages 15-17) Clinical evidence / advanced oncology use
Immunotherapy Durvalumab PD-L1 checkpoint inhibitor under study or use in HPV-mediated cancers as immune-restorative therapy (baba2025humanpapillomavirus pages 15-17) Clinical evidence / advanced oncology use
Advanced therapy siRNA targeting E6/E7 RNA interference suppresses viral oncogene expression, restoring p53/p21 signaling and inhibiting tumor growth; preclinical LNP-siRNA plus cisplatin data are promising (baba2025humanpapillomavirus pages 15-17) Preclinical to early translational
Advanced therapy CRISPR/Cas9 targeting E6/E7 Gene-editing approaches disrupt HPV oncogenes and can trigger tumor cell death or growth arrest in experimental systems (baba2025humanpapillomavirus pages 15-17) Experimental / preclinical
Screening program Pap smear (cytology) Cytologic screening detects LSIL/HSIL and has reduced cervical cancer incidence and mortality where implemented (branda2024humanpapillomavirus(hpv) pages 7-9, baba2025humanpapillomavirus pages 10-11, wu2024unveilingthemultifaceted pages 9-10) Established population screening
Screening program HPV DNA testing Detects high-risk HPV nucleic acids; more accurate/objective than cytology and now preferred by WHO for cervical screening in many settings (maghiar2024skinlesionscaused pages 4-6, jain2023epidemiologymolecularpathogenesis pages 10-12, maghiar2024skinlesionscaused pages 6-7) High-level evidence; preferred modern screening
Screening program VIA (visual inspection with acetic acid) Low-cost screening approach used especially in resource-limited settings to identify acetowhite cervical abnormalities (baba2025humanpapillomavirus pages 10-11, jain2023epidemiologymolecularpathogenesis pages 10-12) Programmatic/public health screening evidence

Table: This table summarizes major current and emerging approaches to HPV treatment, prevention, and screening, spanning lesion-directed therapies, vaccines, systemic cancer treatments, and population screening tools. It is useful for quickly comparing mechanisms and maturity of evidence across interventions.

Key Therapeutic Targets (OpenTargets)

OpenTargets analysis (MONDO:0005161) identified three primary drug targets for HPV infection: TLR7 (toll-like receptor 7; highest association score 0.53, with approved drug imiquimod), IFNAR1 (interferon alpha/beta receptor subunit 1), and IFNAR2 (interferon alpha/beta receptor subunit 2) (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma).

Emerging Therapies

Active Clinical Trials

Multiple Phase 3 clinical trials are currently investigating HPV vaccines and treatments, including: - CERVAVAC® quadrivalent HPV vaccine in HIV-positive women aged 15–25 (NCT06281119; 450 participants) - Nonavalent HPV vaccine efficacy trial (NCT05668572; 12,000 participants) - Dose reduction immunobridging studies in African settings (NCT02834637; 930 participants)

MAXO terms: MAXO:0001017 (vaccination), MAXO:0000004 (surgical procedure), MAXO:0010203 (cryotherapy), MAXO:0000647 (chemotherapy)

13. Prevention

Primary Prevention

Vaccination is the most effective primary prevention strategy. Currently licensed prophylactic vaccines include bivalent (Cervarix: HPV16/18), quadrivalent (Gardasil: HPV6/11/16/18), and nonavalent (Gardasil 9: HPV6/11/16/18/31/33/45/52/58) formulations, as well as Cecolin and Cervavax (jain2023epidemiologymolecularpathogenesis pages 12-13, jain2023epidemiologymolecularpathogenesis pages 10-12). In Australia, HPV prevalence dropped from 22.7% pre-vaccination to 1.5% by 2015 (ashique2023hpvpathogenesisvarious pages 2-4). Countries with robust vaccination programs have witnessed 54–83% declines in high-grade cervical abnormalities and genital warts (jain2023epidemiologymolecularpathogenesis pages 12-13). WHO targets 90% of girls vaccinated by age 15 as part of the cervical cancer elimination strategy (jain2023epidemiologymolecularpathogenesis pages 10-12).

Secondary Prevention

Screening programs form the backbone of secondary prevention. HPV DNA testing is now endorsed by WHO as the preferred cervical cancer screening strategy over conventional cytology (maghiar2024skinlesionscaused pages 4-6). The WHO Global Strategy targets screening 70% of women at ages 35 and 45 and ensuring 90% of women with cervical disease receive proper treatment (jain2023epidemiologymolecularpathogenesis pages 10-12). Concomitant HPV vaccination and screening has been proposed for faster cervical cancer elimination (wu2024unveilingthemultifaceted pages 9-10).

Tertiary Prevention

Management of established CIN and HPV-associated cancers through LEEP, surgical excision, chemotherapy, radiation therapy, and immunotherapy (jain2023epidemiologymolecularpathogenesis pages 12-13, baba2025humanpapillomavirus pages 15-17).

14. Other Species / Natural Disease

Taxonomy and Comparative Biology

Papillomaviruses exhibit extremely high host species specificity, infecting various species including fish, reptiles, birds, and vertebrates (bette2024cottontailrabbitpapillomavirus pages 1-2). Due to this species restriction, human HPV types cannot infect animals, and animal papillomaviruses cannot infect humans.

Natural papillomavirus infections in other species: - Cottontail rabbit (Sylvilagus floridanus): CRPV (Cottontail Rabbit Papillomavirus) causes cutaneous papillomas with high oncogenic potential for progression to squamous cell carcinomas, predominantly on the head and neck (bette2024cottontailrabbitpapillomavirus pages 1-2, bette2024cottontailrabbitpapillomavirus pages 3-5) - Domestic rabbit (Oryctolagus cuniculus): Experimentally susceptible to CRPV infection (bette2024cottontailrabbitpapillomavirus pages 1-2) - Canine species: Canine oral papillomavirus causes papillomas; dogs have immune systems more closely resembling human responses (totain2023developmentofhpv16 pages 7-10)

CRPV E7 inhibits retinoblastoma protein similar to HPV E7, but CRPV E6 differs by binding hDlg/SAP97 rather than p53 (bette2024cottontailrabbitpapillomavirus pages 2-3). Rabbit papillomas and carcinomas closely resemble human HPV-induced tumors (bette2024cottontailrabbitpapillomavirus pages 2-3).

15. Model Organisms

Mouse Models

  • TC-1 cells (C57BL/6): The most commonly used HPV model; C57BL/6 cells expressing HPV16 E6/E7 proteins, used for subcutaneous tumor isograft studies (totain2023developmentofhpv16 pages 1-2). Limitations include restriction to one genetic background and HPV16-only studies.
  • K14-HPV16 transgenic mice: Express E7 constitutively in skin under keratin 14 promoter; develop immune tolerance, limiting utility for immunotherapy testing (totain2023developmentofhpv16 pages 1-2)
  • HPV16 E6-E7 transgenic mice: Genetically engineered using CRISPR/Cas9 to express HPV16 E6/E7 in the cervicovaginal tract, spontaneously developing vaginal-cervical intraepithelial neoplasia (xiurong2024geneticallyengineeredmouse pages 9-10)
  • E7inv conditional transgenic mice: Novel Cre-lox inducible model allowing controlled E7 expression with GFP reporter monitoring (totain2023developmentofhpv16 pages 7-10)

Rabbit Models

Dog Models

Beagle dogs have been developed as HPV16 preclinical models since their immune systems more closely resemble human responses and better reproduce inter-individual MHC diversity variations compared to inbred mouse models (totain2023developmentofhpv16 pages 7-10, totain2023developmentofhpv16 pages 1-2). Lentiviral vectors deliver E7/HPV16 transgenes locally in muscle tissue for vaccine efficacy assessment.

Model Limitations

The TC-1 mouse model, despite being widely used, demonstrated correlations with the clinical failure of the ProCervix therapeutic vaccine: C216 vaccine (similar to ProCervix) induced strong immune responses in both mouse and dog models but failed to adequately eliminate E7-expressing cells, aligning with Phase II clinical trial failure (totain2023developmentofhpv16 pages 7-10, totain2023developmentofhpv16 pages 1-2). This highlights the challenge of translating preclinical immunogenicity to clinical efficacy.

Summary of Ontology Term Suggestions

MONDO: MONDO:0005161 (human papilloma virus infection), MONDO:0005647 (anogenital HPV infection)

HPO Terms: HP:0200043 (Verrucae), HP:0030799 (Condylomata acuminata), HP:0012126 (Cervical squamous cell carcinoma), HP:0100649 (Neoplasm of oral cavity)

GO Terms: GO:0006915 (apoptotic process), GO:0007049 (cell cycle), GO:0043491 (protein kinase B signaling), GO:0060070 (Wnt signaling), GO:0000165 (MAPK cascade), GO:0032481 (regulation of type I interferon production), GO:0006281 (DNA repair)

CL Terms: CL:0000312 (keratinocyte), CL:0002535 (epithelial cell of cervix), CL:0000492 (CD4-positive helper T cell), CL:0000794 (CD8-positive cytotoxic T cell)

UBERON Terms: UBERON:0000002 (uterine cervix), UBERON:0001729 (oropharynx), UBERON:0001245 (anus)

CHEBI Terms: CHEBI:145994 (imiquimod), CHEBI:27899 (cisplatin)

MAXO Terms: MAXO:0001017 (vaccination), MAXO:0000004 (surgical procedure), MAXO:0010203 (cryotherapy), MAXO:0000647 (chemotherapy)

This report synthesizes evidence from 21 peer-reviewed publications (2023–2026), OpenTargets disease-target associations, and 13 registered clinical trials. Information is derived primarily from aggregated disease-level resources including systematic reviews, comprehensive narrative reviews, and GWAS studies. All major claims are supported by cited primary literature.

References

  1. (jain2023epidemiologymolecularpathogenesis pages 3-5): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.

  2. (wu2024unveilingthemultifaceted pages 1-2): Meng Wu, Hui Huang, Ying Tang, Xuze Ren, Xinrui Jiang, Man Tian, and Wei Li. Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1430544, doi:10.3389/fimmu.2024.1430544. This article has 18 citations and is from a peer-reviewed journal.

  3. (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 1-2): Beata Mlynarczyk-Bonikowska and Lidia Rudnicka. Hpv infections—classification, pathogenesis, and potential new therapies. International Journal of Molecular Sciences, 25:7616, Jul 2024. URL: https://doi.org/10.3390/ijms25147616, doi:10.3390/ijms25147616. This article has 109 citations.

  4. (baba2025humanpapillomavirus pages 1-2): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.

  5. (OpenTargets Search: human papillomavirus infectious disease,cervical carcinoma): Open Targets Query (human papillomavirus infectious disease,cervical carcinoma, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (maghiar2024skinlesionscaused pages 4-6): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.

  7. (branda2024humanpapillomavirus(hpv) pages 7-9): Francesco Branda, Grazia Pavia, Alessandra Ciccozzi, Angela Quirino, Nadia Marascio, Simona Gigliotti, Giovanni Matera, Chiara Romano, Chiara Locci, Ilenia Azzena, Noemi Pascale, Daria Sanna, Marco Casu, Giancarlo Ceccarelli, Massimo Ciccozzi, and Fabio Scarpa. Human papillomavirus (hpv) vaccination: progress, challenges, and future directions in global immunization strategies. Vaccines, 12:1293, Nov 2024. URL: https://doi.org/10.3390/vaccines12111293, doi:10.3390/vaccines12111293. This article has 42 citations.

  8. (maghiar2024skinlesionscaused pages 2-4): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.

  9. (baba2025humanpapillomavirus pages 10-11): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.

  10. (jain2023epidemiologymolecularpathogenesis pages 2-3): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.

  11. (malik2023trackinghpvinfection pages 1-2): Shiza Malik, Ranjit Sah, Khalid Muhammad, and Yasir Waheed. Tracking hpv infection, associated cancer development, and recent treatment efforts—a comprehensive review. Vaccines, 11:102, Jan 2023. URL: https://doi.org/10.3390/vaccines11010102, doi:10.3390/vaccines11010102. This article has 61 citations.

  12. (bette2024cottontailrabbitpapillomavirus pages 1-2): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.

  13. (pavelescu2025molecularinsightsinto pages 2-4): Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mindru, Radu Vladareanu, and Antoanela Curici. Molecular insights into hpv-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms, 13:1000, Apr 2025. URL: https://doi.org/10.3390/microorganisms13051000, doi:10.3390/microorganisms13051000. This article has 34 citations.

  14. (bette2024cottontailrabbitpapillomavirus pages 2-3): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.

  15. (olokede2026areviewon pages 6-7): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.

  16. (olokede2026areviewon pages 1-2): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.

  17. (pavelescu2025molecularinsightsinto pages 11-13): Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mindru, Radu Vladareanu, and Antoanela Curici. Molecular insights into hpv-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms, 13:1000, Apr 2025. URL: https://doi.org/10.3390/microorganisms13051000, doi:10.3390/microorganisms13051000. This article has 34 citations.

  18. (olokede2026areviewon pages 16-17): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.

  19. (li2025biomarkersdifferentiatingregression pages 8-9): Xiang Li, Yan Chen, Jing Xiong, Puxiang Chen, Dongdong Zhang, Qing Li, and Peng Zhu. Biomarkers differentiating regression from progression among untreated cervical intraepithelial neoplasia grade 2 lesions. Journal of Advanced Research, 74:391-402, Sep 2025. URL: https://doi.org/10.1016/j.jare.2024.09.009, doi:10.1016/j.jare.2024.09.009. This article has 22 citations and is from a peer-reviewed journal.

  20. (wu2024unveilingthemultifaceted pages 9-10): Meng Wu, Hui Huang, Ying Tang, Xuze Ren, Xinrui Jiang, Man Tian, and Wei Li. Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1430544, doi:10.3389/fimmu.2024.1430544. This article has 18 citations and is from a peer-reviewed journal.

  21. (olokede2026areviewon pages 19-21): Esther Olokede, Jumobi Abeebat Liasu-Thomas, Verity Ghansah, Bassey Atte Inyang, Damilola Rafiat Lamidi, Blessing Chinonye Okoro, and Adebola Ayisat Effa. A review on genetic epidemiology of host genetic structure, viral persistence, and immunological escape in hpv-mediated cervical carcinogenesis. Journal of Pharma Insights and Research, 4:259-295, Apr 2026. URL: https://doi.org/10.69613/d25y8z24, doi:10.69613/d25y8z24. This article has 0 citations.

  22. (legaki2026hpvdrivencervicalcarcinogenesis pages 1-2): Evangelia Legaki, Theofania Lappa, Konstantina-Lida Prasoula, Zoi Kardasi, Emmanouil Kalampokas, Theodoros Kalampokas, Maria G. Roubelakis, Ekaterina Charvalos, and Maria Gazouli. Hpv-driven cervical carcinogenesis: genetic and epigenetic mechanisms and diagnostic approaches. International Journal of Molecular Sciences, 27:803, Jan 2026. URL: https://doi.org/10.3390/ijms27020803, doi:10.3390/ijms27020803. This article has 4 citations.

  23. (li2025biomarkersdifferentiatingregression pages 6-7): Xiang Li, Yan Chen, Jing Xiong, Puxiang Chen, Dongdong Zhang, Qing Li, and Peng Zhu. Biomarkers differentiating regression from progression among untreated cervical intraepithelial neoplasia grade 2 lesions. Journal of Advanced Research, 74:391-402, Sep 2025. URL: https://doi.org/10.1016/j.jare.2024.09.009, doi:10.1016/j.jare.2024.09.009. This article has 22 citations and is from a peer-reviewed journal.

  24. (martinelli2025molecularmechanismsand pages 4-5): Canio Martinelli, Alfredo Ercoli, Silvana Parisi, Giuseppe Iatì, Stefano Pergolizzi, Luigi Alfano, Francesca Pentimalli, Michelino De Laurentiis, Antonio Giordano, and Salvatore Cortellino. Molecular mechanisms and clinical divergences in hpv-positive cervical vs. oropharyngeal cancers: a critical narrative review. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04247-z, doi:10.1186/s12916-025-04247-z. This article has 12 citations and is from a domain leading peer-reviewed journal.

  25. (wu2024unveilingthemultifaceted pages 2-3): Meng Wu, Hui Huang, Ying Tang, Xuze Ren, Xinrui Jiang, Man Tian, and Wei Li. Unveiling the multifaceted realm of human papillomavirus: a comprehensive exploration of biology, interactions, and advances in cancer management. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1430544, doi:10.3389/fimmu.2024.1430544. This article has 18 citations and is from a peer-reviewed journal.

  26. (mlynarczykbonikowska2024hpvinfections—classificationpathogenesis pages 10-11): Beata Mlynarczyk-Bonikowska and Lidia Rudnicka. Hpv infections—classification, pathogenesis, and potential new therapies. International Journal of Molecular Sciences, 25:7616, Jul 2024. URL: https://doi.org/10.3390/ijms25147616, doi:10.3390/ijms25147616. This article has 109 citations.

  27. (baba2025humanpapillomavirus pages 4-6): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.

  28. (kao2026theroleof pages 3-5): Pei-Yu Kao, Jie-Hong Chen, and Kuo-Hu Chen. The role of hpv and hormone in cervical precancer and cancer: molecular pathophysiology and cell biology of disease and treatment. Oncology Research, 34(6):1-10, Jan 2026. URL: https://doi.org/10.32604/or.2026.078219, doi:10.32604/or.2026.078219. This article has 0 citations and is from a peer-reviewed journal.

  29. (baba2025humanpapillomavirus pages 6-8): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.

  30. (pavelescu2025molecularinsightsinto pages 8-10): Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mindru, Radu Vladareanu, and Antoanela Curici. Molecular insights into hpv-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms, 13:1000, Apr 2025. URL: https://doi.org/10.3390/microorganisms13051000, doi:10.3390/microorganisms13051000. This article has 34 citations.

  31. (martinelli2025molecularmechanismsand pages 5-7): Canio Martinelli, Alfredo Ercoli, Silvana Parisi, Giuseppe Iatì, Stefano Pergolizzi, Luigi Alfano, Francesca Pentimalli, Michelino De Laurentiis, Antonio Giordano, and Salvatore Cortellino. Molecular mechanisms and clinical divergences in hpv-positive cervical vs. oropharyngeal cancers: a critical narrative review. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04247-z, doi:10.1186/s12916-025-04247-z. This article has 12 citations and is from a domain leading peer-reviewed journal.

  32. (vallejoruiz2024molecularaspectsof pages 2-3): Verónica Vallejo-Ruiz, Lourdes Gutiérrez-Xicotencatl, Oscar Medina-Contreras, and Marcela Lizano. Molecular aspects of cervical cancer: a pathogenesis update. Frontiers in Oncology, Mar 2024. URL: https://doi.org/10.3389/fonc.2024.1356581, doi:10.3389/fonc.2024.1356581. This article has 51 citations.

  33. (janiszewska2025hpvdrivenoncogenesis—muchmore pages 3-4): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.

  34. (janiszewska2025hpvdrivenoncogenesis—muchmore pages 4-6): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.

  35. (janiszewska2025hpvdrivenoncogenesis—muchmore pages 1-3): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.

  36. (janiszewska2025hpvdrivenoncogenesis—muchmore pages 6-7): J. Janiszewska, ·. M. Kostrzewska‑Poczekaj, ·. M. Wierzbicka, J. C. Brenner, M. Giefing, Ewa Ziętkiewicz, and M. Kostrzewska-Poczekaj. Hpv-driven oncogenesis—much more than the e6 and e7 oncoproteins. Journal of Applied Genetics, 66:63-71, Jun 2025. URL: https://doi.org/10.1007/s13353-024-00883-y, doi:10.1007/s13353-024-00883-y. This article has 35 citations and is from a peer-reviewed journal.

  37. (legaki2026hpvdrivencervicalcarcinogenesis pages 4-5): Evangelia Legaki, Theofania Lappa, Konstantina-Lida Prasoula, Zoi Kardasi, Emmanouil Kalampokas, Theodoros Kalampokas, Maria G. Roubelakis, Ekaterina Charvalos, and Maria Gazouli. Hpv-driven cervical carcinogenesis: genetic and epigenetic mechanisms and diagnostic approaches. International Journal of Molecular Sciences, 27:803, Jan 2026. URL: https://doi.org/10.3390/ijms27020803, doi:10.3390/ijms27020803. This article has 4 citations.

  38. (martinelli2025molecularmechanismsand pages 17-18): Canio Martinelli, Alfredo Ercoli, Silvana Parisi, Giuseppe Iatì, Stefano Pergolizzi, Luigi Alfano, Francesca Pentimalli, Michelino De Laurentiis, Antonio Giordano, and Salvatore Cortellino. Molecular mechanisms and clinical divergences in hpv-positive cervical vs. oropharyngeal cancers: a critical narrative review. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04247-z, doi:10.1186/s12916-025-04247-z. This article has 12 citations and is from a domain leading peer-reviewed journal.

  39. (maghiar2024skinlesionscaused pages 6-7): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.

  40. (jain2023epidemiologymolecularpathogenesis pages 10-12): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.

  41. (karaoglan2024unveilingtherole pages 3-4): Beliz Bahar Karaoğlan and Yüksel Ürün. Unveiling the role of human papillomavirus in urogenital carcinogenesis a comprehensive review. Viruses, 16:667, Apr 2024. URL: https://doi.org/10.3390/v16050667, doi:10.3390/v16050667. This article has 13 citations.

  42. (branda2024humanpapillomavirus(hpv) pages 5-6): Francesco Branda, Grazia Pavia, Alessandra Ciccozzi, Angela Quirino, Nadia Marascio, Simona Gigliotti, Giovanni Matera, Chiara Romano, Chiara Locci, Ilenia Azzena, Noemi Pascale, Daria Sanna, Marco Casu, Giancarlo Ceccarelli, Massimo Ciccozzi, and Fabio Scarpa. Human papillomavirus (hpv) vaccination: progress, challenges, and future directions in global immunization strategies. Vaccines, 12:1293, Nov 2024. URL: https://doi.org/10.3390/vaccines12111293, doi:10.3390/vaccines12111293. This article has 42 citations.

  43. (jain2023epidemiologymolecularpathogenesis pages 12-13): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.

  44. (maghiar2024skinlesionscaused pages 7-9): Laura Maghiar, Mircea Sandor, Liliana Sachelarie, Ruxandra Bodog, and Anca Huniadi. Skin lesions caused by hpv—a comprehensive review. Biomedicines, 12:2098, Sep 2024. URL: https://doi.org/10.3390/biomedicines12092098, doi:10.3390/biomedicines12092098. This article has 28 citations.

  45. (jain2023epidemiologymolecularpathogenesis pages 22-24): Meenu Jain, Dhananjay Yadav, Urmila Jarouliya, Vishal Chavda, Arun Kumar Yadav, Bipin Chaurasia, and Minseok Song. Epidemiology, molecular pathogenesis, immuno-pathogenesis, immune escape mechanisms and vaccine evaluation for hpv-associated carcinogenesis. Pathogens, 12:1380, Nov 2023. URL: https://doi.org/10.3390/pathogens12121380, doi:10.3390/pathogens12121380. This article has 80 citations.

  46. (baba2025humanpapillomavirus pages 15-17): Sadaf Khursheed Baba, Shahad Shahdad Eissa Alblooshi, Reem Yaqoob, Shalini Behl, Mansour Al Saleem, Emad A. Rakha, Fayaz Malik, Mayank Singh, Muzafar A. Macha, Mohammed Kalim Akhtar, Walid A. Houry, Ajaz A. Bhat, Asma Al Menhali, Zhi-Ming Zheng, and Sameer Mirza. Human papilloma virus (hpv) mediated cancers: an insightful update. Journal of Translational Medicine, Apr 2025. URL: https://doi.org/10.1186/s12967-025-06470-x, doi:10.1186/s12967-025-06470-x. This article has 79 citations and is from a peer-reviewed journal.

  47. (ashique2023hpvpathogenesisvarious pages 2-4): Sumel Ashique, Afzal Hussain, Neda Fatima, and Mohammad A. Altamimi. Hpv pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. VirusDisease, 34:172-190, May 2023. URL: https://doi.org/10.1007/s13337-023-00824-z, doi:10.1007/s13337-023-00824-z. This article has 45 citations.

  48. (bette2024cottontailrabbitpapillomavirus pages 3-5): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.

  49. (totain2023developmentofhpv16 pages 7-10): Emmanuelle Totain, Loïc Lindner, Nicolas Martin, Yolande Misseri, Alexandra Iché, Marie-Christine Birling, Tania Sorg, Yann Herault, Alain Bousquet-Melou, Pascale Bouillé, Christine Duthoit, Guillaume Pavlovic, and Severine Boullier. Development of hpv16 mouse and dog models for more accurate prediction of human vaccine efficacy. Laboratory Animal Research, Jun 2023. URL: https://doi.org/10.1186/s42826-023-00166-3, doi:10.1186/s42826-023-00166-3. This article has 2 citations.

  50. (totain2023developmentofhpv16 pages 1-2): Emmanuelle Totain, Loïc Lindner, Nicolas Martin, Yolande Misseri, Alexandra Iché, Marie-Christine Birling, Tania Sorg, Yann Herault, Alain Bousquet-Melou, Pascale Bouillé, Christine Duthoit, Guillaume Pavlovic, and Severine Boullier. Development of hpv16 mouse and dog models for more accurate prediction of human vaccine efficacy. Laboratory Animal Research, Jun 2023. URL: https://doi.org/10.1186/s42826-023-00166-3, doi:10.1186/s42826-023-00166-3. This article has 2 citations.

  51. (xiurong2024geneticallyengineeredmouse pages 9-10): Du Xiurong, Zhou Xin, Yang Neng, Deng Li, Wang Yanzhou, Ling Kaijian, and Liang Zhiqing. Genetically engineered mouse model of hpv16 e6-e7 with vaginal-cervical intraepithelial neoplasia and decreased immunity. May 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e29881, doi:10.1016/j.heliyon.2024.e29881. This article has 1 citations.

  52. (bette2024cottontailrabbitpapillomavirus pages 16-17): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.

  53. (bette2024cottontailrabbitpapillomavirus pages 19-20): Michael Bette and Robert Mandic. Cottontail rabbit papillomavirus (crpv) related animal models for head and neck cancer research: a comprehensive review of the literature. Viruses, 16:1722, Oct 2024. URL: https://doi.org/10.3390/v16111722, doi:10.3390/v16111722. This article has 0 citations.

Artifacts